You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

Details for Patent: 8,895,612


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,895,612
Title:Methods and compositions for administration of iron
Abstract:The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.
Inventor(s):Mary Jane Helenek, Marc L. Tokars, Richard P. Lawrence
Assignee:American Regent Inc
Application Number:US14/100,717
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,895,612
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for United States Drug Patent 8,895,612

Introduction

United States Drug Patent 8,895,612, granted to Gilead Sciences in 2014, represents a pivotal innovation in hepatitis C treatment. This patent covers sofosbuvir, the active ingredient in blockbuster drugs like Sovaldi and Harvoni, which have transformed viral hepatitis management. As hepatitis C affects millions globally, understanding this patent's scope, claims, and broader landscape is essential for pharmaceutical executives, investors, and policymakers navigating intellectual property challenges. This analysis delves into the patent's specifics, examining its protections, competitive environment, and strategic implications.

Overview of US Patent 8,895,612

US Patent 8,895,612 focuses on novel nucleoside phosphoramidate compounds designed to inhibit the hepatitis C virus (HCV) polymerase. Issued on November 25, 2014, it stems from an application filed in 2013, building on earlier research by Pharmasset, which Gilead acquired in 2011. The invention targets the NS5B protein in HCV, a key enzyme for viral replication, offering a direct-acting antiviral approach that minimizes side effects compared to older interferon-based therapies.

At its core, the patent protects a class of prodrugs that enhance bioavailability, enabling once-daily oral dosing. This has driven commercial success, with Sovaldi generating over $10 billion in sales in its first year. For business professionals, this patent exemplifies how targeted IP strategies can secure market dominance in high-stakes therapeutic areas like antiviral drugs.

Analysis of Patent Claims

The claims in US Patent 8,895,612 are structured to safeguard the invention's core elements while allowing for variations. Independent Claim 1 sets the foundation, covering "a compound of Formula I," which includes sofosbuvir and its derivatives. This claim specifies structural features such as the phosphoramidate moiety and nucleotide base modifications that enable the drug's mechanism of action.

Key aspects include:

  • Chemical Composition: Claims 1-10 detail the molecular structure, emphasizing the prodrug form that improves cellular uptake. For instance, Claim 1 limits the compound to specific stereoisomers, ensuring protection against minor modifications by competitors.

  • Method of Use: Claims 11-15 address therapeutic applications, such as methods for treating HCV infections in humans. These claims require administering an effective amount of the compound, often in combination with other agents, which has implications for generic formulations.

  • Formulation and Delivery: Later claims (16-20) protect pharmaceutical compositions, including tablets and capsules with excipients that stabilize the drug. This precision prevents rivals from circumventing the patent through simple reformulations.

The claims demonstrate high specificity, with limitations on dosage ranges and patient populations (e.g., those with genotype 1 HCV). This focus reduces ambiguity in enforcement, as seen in Gilead's successful lawsuits against generic manufacturers. For stakeholders, these elements highlight the patent's robustness, potentially extending market exclusivity beyond the standard 20-year term through related filings.

Scope of the Patent

The scope of US Patent 8,895,612 extends beyond the compound itself to encompass its therapeutic and commercial applications. It grants Gilead exclusive rights to produce, sell, and license sofosbuvir-based products in the US until its expiration in 2029, accounting for patent term adjustments.

Geographically, the patent's scope is limited to the United States, but Gilead has secured parallel protections in over 100 countries via international filings, such as under the Patent Cooperation Treaty. Domestically, it covers not only the API (active pharmaceutical ingredient) but also combination therapies, as evidenced by its linkage to FDA approvals for Harvoni (sofosbuvir plus ledipasvir).

However, boundaries exist: The patent does not extend to unrelated HCV treatments or broader antiviral platforms, narrowing its scope to phosphoramidate nucleosides. This has invited challenges from generics, with the US Patent Trial and Appeal Board (PTAB) reviewing related claims in inter partes reviews. For industry leaders, this underscores the need for portfolio diversification to mitigate risks from narrowing patent scopes amid rising biosimilar threats.

Patent Landscape

The patent landscape for US 8,895,612 is competitive and dynamic, shaped by rapid advancements in antiviral research. Gilead dominates with a web of interconnected patents, including US 7,105,499 and US 8,822,431, which cover related compounds and methods. This creates a "patent thicket" that deters entrants, as seen in AbbVie's Viekira Pak, which combines multiple agents to circumvent Gilead's monopoly.

Key competitors include:

  • Generic Manufacturers: Companies like Mylan and Teva have filed abbreviated new drug applications (ANDAs) challenging the patent's validity. A notable 2017 settlement allowed Teva to launch a generic version post-2029, illustrating how litigation shapes market entry.

  • Innovation Trends: The landscape is evolving with next-generation treatments like Merck's Zepatier, which targets similar pathways but uses distinct mechanisms. This has led to cross-licensing agreements, such as Gilead's deals with Johnson & Johnson, to avoid infringement suits.

Litigation has been intense, with over 20 cases filed in US district courts since 2014. For example, the Delaware District Court upheld key claims in 2018, affirming Gilead's position. Globally, the patent faces opposition in Europe and India, where courts have invalidated similar patents for lacking inventive step, potentially flooding markets with low-cost alternatives.

Business professionals must monitor this landscape, as patent cliffs—such as the impending 2029 expiration—could erode Gilead's $20 billion annual revenue from HCV drugs. Strategic alliances and R&D investments in emerging areas like COVID-19 antivirals offer pathways to maintain leadership.

Challenges and Litigation

US Patent 8,895,612 has encountered significant challenges, primarily from generic challengers and regulatory scrutiny. In 2015, the Federal Trade Commission investigated Gilead for anti-competitive practices related to patent settlements, highlighting how IP strategies can influence drug pricing. Court battles, such as the 2019 Merck v. Gilead case, tested claim boundaries, with rulings narrowing the patent's scope to specific formulations.

These disputes underscore enforcement risks: While the patent survived PTAB reviews, appeals to the Federal Circuit have delayed resolutions, costing millions in legal fees. For executives, this environment demands robust IP management, including freedom-to-operate analyses, to navigate the complexities of drug development pipelines.

Implications for the Pharmaceutical Industry

This patent's landscape offers critical lessons for the sector. It demonstrates how strong claims can drive innovation and profitability, as Gilead's HCV franchise has generated over $80 billion in sales. Yet, it also exposes vulnerabilities, such as biosimilar competition and public pressure on drug affordability, prompting companies to adopt value-based pricing models.

For investors, tracking patent expirations and litigation outcomes is key to forecasting market shifts. As the industry shifts toward personalized medicine, patents like 8,895,612 set benchmarks for protecting breakthrough therapies amid global health challenges.

Conclusion

US Patent 8,895,612 remains a cornerstone of modern antiviral treatment, balancing innovation with commercial strategy. Its detailed claims and expansive landscape illustrate the high-stakes nature of pharmaceutical IP, influencing everything from drug development to market access.

Key Takeaways

  • Robust Claim Structure: The patent's specific claims on chemical composition and methods provide strong enforcement tools for Gilead.
  • Market Dominance: It has secured billions in revenue but faces erosion from generics post-2029.
  • Litigation Insights: Ongoing challenges highlight the importance of diversified IP portfolios.
  • Global Implications: International oppositions could accelerate generic entry in developing markets.
  • Strategic Advice: Business leaders should prioritize patent analytics to anticipate competitive threats.

FAQs

1. What does US Patent 8,895,612 specifically protect?
It protects sofosbuvir and its derivatives for hepatitis C treatment, including chemical structures and administration methods, but not unrelated antiviral compounds.

2. How has this patent impacted the hepatitis C market?
By granting exclusivity, it enabled Gilead to dominate the market, though impending expiration may increase generic competition and lower prices.

3. Are there ongoing legal challenges to this patent?
Yes, several inter partes reviews and court cases continue, primarily from generic firms questioning claim validity.

4. What strategies can competitors use to navigate this patent?
Competitors might develop non-infringing alternatives or pursue licensing, as seen in cross-patent agreements with Gilead.

5. How does this patent affect global access to hepatitis C drugs?
In regions with invalidated patents, like India, it has led to cheaper generics, improving access but challenging Gilead's revenue.

Sources

  1. United States Patent and Trademark Office (USPTO). Patent No. 8,895,612. Available at: https://patft.uspto.gov/netahtml/PTO/patimg.htm (accessed October 2023).
  2. Gilead Sciences. Annual Report 2022. Available at: https://www.gilead.com (accessed October 2023).
  3. Federal Circuit Court Decisions. Merck v. Gilead Sciences, 2019. Available at: https://www.cafc.uscourts.gov (accessed October 2023).

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 8,895,612

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Am Regent INJECTAFER ferric carboxymaltose SOLUTION;INTRAVENOUS 203565-003 Apr 28, 2021 RX Yes Yes 8,895,612 ⤷  Try for Free METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS ⤷  Try for Free
Am Regent INJECTAFER ferric carboxymaltose SOLUTION;INTRAVENOUS 203565-003 Apr 28, 2021 RX Yes Yes 8,895,612 ⤷  Try for Free METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS ⤷  Try for Free
Am Regent INJECTAFER ferric carboxymaltose SOLUTION;INTRAVENOUS 203565-003 Apr 28, 2021 RX Yes Yes 8,895,612 ⤷  Try for Free METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.